Private markets & real assetsJefferies
Healthcare Private Equity Nears a Turning Point
Obesity drugs (GLP-1)Artificial intelligence
Our summary
Healthcare private equity is moving toward a seller-friendlier phase as liquidity pressure, new deal structures and AI reshape transactions.
- Sponsors are under pressure to return capital to limited partners, while Jefferies identifies pharma services as its busiest 2026 middle-market vertical, especially businesses generating roughly $30 million to $60 million of EBITDA.
- Carve-outs in medtech, joint ventures between strategics and sponsors, and take-privates of underperforming public companies are gaining attention as sponsor-to-sponsor deals remain difficult.
- GP-led secondary volume reached $115 billion in 2025, up 53% from $75 billion in 2024, with continuation vehicles allowing sponsors to retain selected assets while providing liquidity to existing investors.
- AI is accelerating data analysis, scenario testing and investment committee preparation, while competitive bidding remains the mechanism that connects intrinsic value with the market-clearing price.
- GLP-1 therapies are expanding deal opportunities across pharma services, contract manufacturing, sterile injectables, prefilled syringes and specialized packaging; the FDA approved tirzepatide for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024.
Takeaway: Investors should prioritize operational value creation, clear exit routes and healthcare businesses positioned along the GLP-1 supply chain, while reassessing assets bought at peak valuations in 2020 and 2021.
Published by Jefferies. Summary by HF Best Ideas.